

TRACK RECORDS AND CLIENTS

Evotec, with its broad expertise and services, its repeat business and strategic alliances, is perfectly positioned to be your drug discovery services provider of choice. We are aware of the fact that it takes much more than just the highest quality services to develop new drugs, but nevertheless this is the most important starting point. Evotec delivers an industrialised, high-tech, and comprehensive infrastructure to our partners.

Evotec is one of the few drug discovery businesses that can execute a comprehensive outsourcing strategy. In significant large-scale, multi-target deals, Evotec's customers work with our scientists to progress discovery programmes from target through to lead optimisation using the Company's integrated drug discovery platform.

Evotec has a broad client base ranging from venture capital firms to virtual biotechs to large pharmaceutical companies. We are a truly global company with clients in the United States, Europe and Japan. We have a loyal client base with many long-term agreements as well as regular repeat clients that keep coming back with project after project as Evotec delivers the drug discovery solutions and value they need to drive their discovery programmes forward. ●

janssen Integrated, early stage collaboration in Alzheimer's disease to identify and progress novel treatments, deal structure includes research funding, milestones and royalties

ucb Integrated chemistry, biology and DMPK team at Evotec, working with UCB scientists across various sites on multiple targets, deal structure includes research funding, milestones and royalties

BAYER Integrated five-year multi-target collaboration in the field of endometriosis, deal structure includes upfront payment plus milestones and royalties

CHDI Integrated chemistry and biology team at Evotec, including high-content assays and lead optimisation, recently extended to 2016 (started in 2006)

»Evotec's knowledge in Alzheimer's disease greatly enabled this collaboration«

»Evotec is the ideal partner to provide the resource bandwidth and drug-hunting expertise«

»Our new collaboration with Evotec will perfectly complement our activities in this field of high unmet medical need«

»We are impressed by Evotec's breadth of drug discovery expertise«



Imprint
Editor: Evotec AG;
Chief Editor: Michael Bayer
Content: Mario Polywka, Steven Hutchins
Design: alessandridesign, Thomas Piribauer
Programming: bgcc

Contact us:



Mario Polywka
 Chief Operating Officer
 mario.polywka@evotec.com



Steven Hutchins
 Executive Vice President,
 Business Development
 steven.hutchins@evotec.com